There was a mistake in the part of OVX rats model and RRP intervention in the original publication. The dosage of EV (0.1 mg/1 mL/100 g) and RRP (2.5 g/1 mL/100 g) should be corrected as EV (0.01 mg/1 mL/100 g) and RRP (0.25 g/ 1 mL/100 g).
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There was a mistake in the part of OVX rats model and RRP intervention in the original publication. The dosage of EV (0.1 mg/1 mL/100 g) and RRP (2.5 g/1 mL/100 g) should be corrected as EV (0.01 mg/1 mL/100 g) and RRP (0.25 g/ 1 mL/100 g). In addition, the names and serial numbers of compounds in Supplement Fig. 1 were unfortunately incorrect. The figure is reproduced here.
Moreover, the authors carelessly uploaded the wrong images ( Fig. 6a) for the Sham Group and OVX Group. The figure below shows the correct images. The error does not affect the interpretation and conclusion of the study. The authors apologize for any inconvenience that this error may have caused. may also increase OPG expression and secretion, which leads to an inhibition of the RANKL/cathepsin Kmediated bone resorption. In addition, the increased expression of β-catenin further activates OPG/RANKL signaling. The sign (↓) means promoting. The sign (┴) means inhibiting. CTSK, cathepsin K; DKK1, Dickkopfrelated protein-1; GSK-3β, glycogen synthase kinase 3β; IGF-1, insulin-like growth factor-1; OPG, osteoprotegerin; RANKL, receptor activator for nuclear factor-κB ligand
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